Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.

Jie LiuShrita PatelNilo B CaterLarry WuSusan HuyckSteven G TerraAnne HickmanAmanda DarekarAnnpey PongIra Gantz

Published in: Diabetes, obesity & metabolism (2020)

Treatment with ertugliflozin was associated with reductions in HbA1c, FPG, BW and SBP, and was generally well tolerated in E/SE Asian patients with T2DM. ClinicalTrials.gov identifier: NCT01986855, NCT01999218, NCT01958671, NCT02099110, NCT02036515, NCT02033889, NCT02226003.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
type diabetes
peritoneal dialysis
weight loss
smoking cessation